MRSN

Mersana Therapeutics, Inc. (MRSN) Business Model Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Revenue Model

Revenue is still generated primarily from product sales, with TTM revenue per share at 3.37 and a very high gross margin of 98.3%.

The business remains unprofitable at the operating and net levels, with TTM operating margin of -3.13% and net margin of -3.33%.

Profitability

Gross margin remains exceptionally high at 98.3%, but that has not translated into operating leverage because SG&A and R&D remain elevated relative to revenue.

TTM operating return metrics remain deeply negative, including ROIC of -2.42% and ROCE of -2.71%.

Balance Sheet

Liquidity is acceptable with a current ratio of 1.39 and cash ratio of 1.30, supported by cash per share of 11.31.

However, equity and tangible book value remain negative, and solvency metrics are weak despite low reported debt levels.

Cash Flow

TTM free cash flow and operating cash flow remain negative, with FCF yield at -37.9% and operating cash flow ratio at -1.27.

Cash conversion remains poor despite strong receivables collection, as the cash conversion cycle is heavily distorted by very large payables outstanding.

Growth Scalability

The model shows strong gross margin scalability, but current expense structure prevents that from flowing through to earnings.

Asset turnover is modest at 0.27, indicating limited efficiency in converting assets into revenue.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mersana Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →